Abeona Therapeutics (ABEO) Cash from Financing Activities (2012 - 2026)

Abeona Therapeutics' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 132.83% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at $17.0 million (down 80.05% YoY), while the FY2025 annual figure was $26.0 million, down 74.99% from the prior year.
• Cash from Financing Activities was -$2.2 million for Q1 2026 at Abeona Therapeutics, down from $3.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $73.7 million in Q2 2024 to a low of -$2.2 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged $14.1 million across 5 years, with a median of $6.6 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities surged 636100.0% in 2024, then sank 132.83% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $42.8 million in 2022, then tumbled by 82.54% to $7.5 million in 2023, then retreated by 28.83% to $5.3 million in 2024, then tumbled by 31.99% to $3.6 million in 2025, then tumbled by 161.48% to -$2.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$2.2 million (Q1 2026), $3.6 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.